Clinical trials: Refractory Neoplasm
T-cell Non-Hodgkin's Lymphoma
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
This is a Phase II, multicenter, single-arm, open-label study of oral lenalidomide monotherapy administered to subjects with relapsed or refractory T-cell lymphoma.
- Trial name
- EXPECT (NCT00655668)
- Testing
- Lenalidomide
- Where
- 45 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Celgene
Prostate Cancer
A Study of Olaratumab (IMC-3G3) in Prostate Cancer
This is a study evaluating the safety and efficacy of the monoclonal antibody olaratumab plus mitoxantrone plus prednisone compared to mitoxantrone plus prednisone in metastatic castration-refractory prostate cancer following…
- Trial name
- NCT01204710
- Testing
- Olaratumab, Mitoxantrone, Prednisone
- Where
- 40 sites in Belgium, Czechia and 5 more
- Volunteers
- 123 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer
A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer
The purpose of this study is to determine whether NK012 is safe and effective in the treatment of relapsed small cell lung cancer.
- Trial name
- NCT00951613
- Testing
- NK012
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Nippon Kayaku Co., Ltd.
Metastatic Hormone Refractory Prostate Cancer
PHA-739358 for Treatment of Hormone Refractory Prostate Cancer
To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based 1st-line chemotherapy for HRPC based on PSA…
- Trial name
- NCT00766324
- Testing
- PHA-739358
- Where
- Italy
- Volunteers
- 118 people
- Sponsor
- Nerviano Medical Sciences
Neuroblastoma, Pheochromocytoma
Expanded Access Protocol Using 131I-MIBG
Protocol JDI2007-01 is an Expanded Access Protocol with therapeutic 131I-MIBG for patients with neuroblastoma or pheochromocytoma / paraganglioma, who otherwise do not qualify for available treatments, or where approved treatment…
- Conditions
- Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT01590680
- Testing
- I-131 MIBG
- Where
- 19 sites in United States
- Sponsor
- Jubilant DraxImage Inc.
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
The purpose of this study is to determine safety and tolerability of combination therapy of SGN-40 with gemcitabine and rituximab for the treatment of lymphoma.
- Trial name
- NCT00655837
- Testing
- SGN-40, rituximab, gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Acute Myeloid Leukemia
Study of AMV564 in Patients With AML
This is a first in human, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of AMV564.
- Trial name
- NCT03144245
- Testing
- AMV564, AMV564 in combination with pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 53 people
- Sponsor
- Amphivena Therapeutics, Inc.
Follicular Lymphoma, Refractory Follicular Lymphoma
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation
The purpose of this research study is to learn about the effectiveness and safety of the study drug, tazemetostat, in adults with relapsed/refractory follicular lymphoma whose tumours do not have an "EZH2 gain-of-function"…
- Trial name
- Mandolin (NCT06068881)
- Testing
- Tazverik (Tazemetostat)
- Sponsor
- Epizyme, Inc.
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Primary Objective To evaluate the preliminary efficacy of Purinostat Mesylate for Injection in patients with relapsed or refractory Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL). Secondary Objectives 1.
- Trial name
- NCT06485219
- Testing
- 11.2 mg/m2 Purinostat Mesylate, 15 mg/m2 Purinostat Mesylate
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Lymphoma
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma.
- Trial name
- CITADEL-203 (NCT03126019)
- Testing
- Parsaclisib
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 126 people
- Sponsor
- Incyte Corporation
Follicular Lymphoma
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
The study is being conducted to evaluate the efficacy and safety of SHR2554 in Patients with Relapsed or Refractory Follicular Lymphoma
- Trial name
- NCT06368167
- Testing
- SHR2554
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Leukemia, B-Cell
Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL
The purpose of the study is to determine the maximum tolerated dose (MTD) in patients with acute lymphoblastic leukemia (ALL) and to determine the safety and tolerability of increasing doses and different infusion times of AFM11…
- Trial name
- NCT02848911
- Testing
- AFM11
- Where
- 12 sites in Austria, Czechia and 3 more
- Volunteers
- 17 people
- Sponsor
- Affimed GmbH
Multiple Myeloma
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess the safety and benefits of the investigational study drug, KW-2478, when given with bortezomib (Velcade®), a drug approved for the treatment of Multiple Myeloma (MM).
- Trial name
- NCT01063907
- Testing
- KW-2478, Bortezomib
- Where
- 26 sites in United States, Philippines and 1 more
- Volunteers
- 95 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Non-Hodgkin's Lymphoma
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel T-Cell bispecific (TCB), MBS303, administered…
- Trial name
- NCT05806099
- Testing
- MBS303
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Waldenstrom's Macroglobulinemia
Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 90% of the patients with Waldenström's macroglobulinemia.
- Trial name
- 8400-401 (NCT02092909)
- Testing
- IMO-8400
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Colorectal Neoplasms
Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
This national, multicenter, open-label phase 2 study without any control arm aims to evaluate the activity of cetuximab monotherapy in the treatment of refractory colorectal cancer in subjects with K-RAS mutated and FcγRIIa…
- Trial name
- MUTEX (NCT01450319)
- Testing
- Cetuximab
- Where
- 9 sites in Spain
- Volunteers
- 73 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Small Cell Lung Cancer
A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC
A study to evaluate the safety and tolerability of AMG 119 in adult subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC) and determine the appropriate cell dose.
- Trial name
- NCT03392064
- Testing
- AMG 119
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Amgen
Non Hodgkin Lymphoma
CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma
To evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor T cell infusion in the treatment of relapsed or refractory CD19 positive non-Hodgkin's lymphoma.
- Trial name
- NCT04237428
- Testing
- CD19 CAR-T cells infusion
- Where
- China
- Volunteers
- 20 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Chronic Lymphocytic Leukemia
Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to see at what dose MDX-1342, a monoclonal antibody, is safe and tolerable for patients with chronic lymphocytic leukemia (CLL).
- Trial name
- MDX1342-02 (NCT00593944)
- Testing
- MDX-1342
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Hematologic Malignancy
Besponsa Post Marketing Surveillance Study
Besponsa is approved for the treatment of R/R B-cell ALL in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS.
- Trial name
- NCT04307134
- Testing
- Inotuzumab ozogamicin
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Pfizer